Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 926 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Plaque Psoriasis
Interventions: ESK-001, Placebo; Drug
Lead sponsor: Alumis Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 33 more

Conditions: Plaque Psoriasis, Skin Diseases, Papulosquamous, Skin Diseases
Interventions: AM001 Cream, 7.5%, Placebo of AM001 Cream; Drug
Lead sponsor: AmDerma; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Miami, Florida • Fridley, Minnesota • Albuquerque, New Mexico + 2 more

Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Periodontal Disease
Interventions: doxycycline, vancomycin; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 178 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: New York, New York

Conditions: Psoriasis
Interventions: Acitretin 17.5 mg/day; Drug
Lead sponsor: Frankel, Amylynne, M.D.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriasis Vulgaris
Interventions: LEO 90100, Vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Psoriasis, Metabolic Syndrome
Interventions: Not listed
Lead sponsor: Tufts Medical Center; Other
Eligibility: 10 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Psoriasis
Interventions: Placebo, Adalimumab; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Little Rock, Arkansas • Bakersfield, California • Macon, Georgia + 5 more

Conditions: Palmoplantar Pustulosis
Interventions: RIST4721, Placebo; Drug
Lead sponsor: Aristea Therapeutics, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 19
States / cities: Birmingham, Alabama • Bryant, Arkansas • San Diego, California + 16 more

Conditions: Dermatitis, Atopic
Interventions: Combination therapy GSK2894512 Cream A + GSK2894512 Cream B, Combination therapy Vehicle Cream A + Vehicle Cream B; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Psoriasis, Coronary Artery Disease
Interventions: CCTA Scan (Coronary CT Angiogram); Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Psoriasis
Interventions: BMS-986165, Placebo, Apremilast; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 67
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 57 more

Conditions: Psoriasis
Interventions: M518101; Drug
Lead sponsor: Maruho North America Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 31
States / cities: Mesa, Arizona • Bakersfield, California • Los Angeles, California + 26 more

Conditions: Plaque Psoriasis
Interventions: (CP-6890,550) Tofacitinib, Placebo, (CP-690,550) Tofacitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 5
States / cities: Los Angeles, California • Tampa, Florida • Dallas, Texas + 1 more

Conditions: Psoriatic Nail, Psoriasis Vulgaris, Psoriasis
Interventions: Apremilast; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Nail Psoriasis
Interventions: Deucravacitinib; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 99 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Chronic Plaque-type Psoriasis
Interventions: CJM112, Secukinumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 18
States / cities: Anniston, Alabama • Anaheim, California • Encino, California + 14 more

Conditions: Psoriasis
Interventions: Not listed
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 20 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Psoriasis
Interventions: Aminopterin; Drug
Lead sponsor: Syntrix Biosystems, Inc.; Industry
Eligibility: 21 Years to 59 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Psoriasis
Interventions: Tacrolimus Cream; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 12 Years and older
Enrollment: 658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 27
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 24 more

Conditions: Generalized Pustular Psoriasis
Interventions: Spesolimab; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Irvine, California • Fargo, North Dakota

Conditions: Psoriasis
Interventions: Riboflavin, Placebo; Drug · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Psoriasis
Interventions: Tetrathiomolybdate (TM); Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: CorEvitas; Network
Eligibility: 18 Years and older
Enrollment: 91,758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2100
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Plaque Psoriasis
Interventions: Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%), Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis

Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)

Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects?

LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

Peds Metabolic Syndrome in Psoriasis

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream

Premature Coronary Artery Disease (CAD) in Severe Psoriasis

Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis

Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis

An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Deucravacitinib for the Treatment of Nail Psoriasis

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment

Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis

A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis

A Study of Tetrathiomolybdate in the Treatment of Psoriasis Vulgaris

CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry

Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis